Clovis Oncology Inc. (NASDAQ:CLVS) was up 3% during mid-day trading on Tuesday . The company traded as high as $24.57 and last traded at $24.10, with a volume of 913,646 shares. The stock had previously closed at $23.39.

A number of equities research analysts have issued reports on CLVS shares. WallachBeth Capital reduced their target price on shares of Clovis Oncology from $30.00 to $22.00 and set a “hold” rating on the stock in a report on Monday, May 9th. Piper Jaffray Cos. reiterated a “neutral” rating and set a $14.00 target price on shares of Clovis Oncology in a report on Thursday, August 25th. Zacks Investment Research lowered shares of Clovis Oncology from a “buy” rating to a “hold” rating in a report on Tuesday, May 10th. SunTrust Banks Inc. increased their target price on shares of Clovis Oncology from $25.00 to $30.00 and gave the stock a “buy” rating in a report on Wednesday, August 24th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $30.00 target price on shares of Clovis Oncology in a report on Thursday, June 30th. Six investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $30.48.

The company’s 50-day moving average price is $16.46 and its 200-day moving average price is $16.24. The company’s market cap is $932.49 million.

Clovis Oncology (NASDAQ:CLVS) last released its earnings results on Monday, August 8th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.13) by $0.06. During the same quarter in the previous year, the company earned ($2.10) earnings per share. On average, analysts predict that Clovis Oncology Inc. will post ($9.33) earnings per share for the current fiscal year.

An institutional investor recently bought a new position in Clovis Oncology stock. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Clovis Oncology Inc. (NASDAQ:CLVS) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund bought 33,500 shares of the biopharmaceutical company’s stock, valued at approximately $1,172,000. Connor Clark & Lunn Investment Management Ltd. owned 0.09% of Clovis Oncology as of its most recent filing with the SEC.

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.